Research onlyGrowth hormoneSubcutaneousEvidence 3/5

CJC-1295

Also known as: DAC:GRF

Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.

Browse guides Buy / compare source

Drug class

GHRH analog (with or without DAC)

Primary targets

GHRH receptor

Dose reference

1–2 mg weekly (DAC, research)

Half-life

~6–8 days (DAC)

Developer / origin

ConjuChem (original)

Reference year

2005

Evidence score

3/5 - Limited human pharmacology

Evidence 3/5

Limited human pharmacology

CJC-1295 has human pharmacology data showing prolonged GH/IGF-1 stimulation, but it is not approved and lacks long-term outcome evidence.

Limited human pharmacology or small clinical evidence.

Evidence basis

Human GH/IGF-1 pharmacology
Long-acting GHRH analog data
No approved indication

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

CJC-1295 guides

Read the matching guide or adjacent research pages for more context.

Sermorelin: Complete Guide to the GH-Releasing Peptide (2026)Sermorelin is a GHRH (growth-hormone-releasing hormone) analog. It's not a GLP-1 despite being often searched alongside them. Here's what sermorelin actually does and where it stands legally.Ipamorelin vs Sermorelin: Growth Hormone Peptides ComparedIpamorelin and sermorelin both stimulate growth hormone release, but they work through different receptors and have very different regulatory histories.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Ipamorelin

NNC 26-0161

3/5

Growth hormoneResearch only

Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.

Details Guide

Tesamorelin

Egrifta

5/5

Growth hormoneApproved

Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Details

Category hub

Open the category page for the full comparison table and FAQ.

Growth Hormone Peptides

Compare growth hormone peptides including ipamorelin, CJC-1295 and tesamorelin by GH-axis mechanism, approval status, half-life and evidence score.